BridgeMD
New treatment option for Myelodysplastic Syndromes
Official title Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia
ClinicalTrials.gov ID: NCT06599762
What this study is testing
What is Tranexamic acid?
Tranexamic acid is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for myelodysplastic syndromes.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are serious, life changing blood cancers. Patients with MDS and AML commonly experience complications related to bleeding, which affect patient quality-of-life and can sometimes lead to hospitalization or death.
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Master platform
- Age ≥ 18 years
- Diagnosis of myelodysplastic syndromes, myelodysplastic/myeloproliferative neoplasm or acute myeloid leukemia MYELO-CAN TXA
- Receipt of less-intensive chemotherapy (includes both frontline and relapsed/refractory setting)
- Severe thrombocytopenia (platelets ≤ 30x10\^9/L or platelets ≤ 50x10\^9/L prior to chemotherapy initiation)
You likely can't join if
- Master platform exclusion criteria:
- Participant is deemed unlikely to survive \>30 days (as determined by clinical team)
- Participant unable to provide informed consent MYELO-CAN TXA exclusion criteria:
- Known allergy to tranexamic acid
- Active thromboembolic disease
- Active ischemic heart disease
See the full eligibility criteria
- Master platform
- Age ≥ 18 years
- Diagnosis of myelodysplastic syndromes, myelodysplastic/myeloproliferative neoplasm or acute myeloid leukemia MYELO-CAN TXA
- Receipt of less-intensive chemotherapy (includes both frontline and relapsed/refractory setting)
- Severe thrombocytopenia (platelets ≤ 30x10\^9/L or platelets ≤ 50x10\^9/L prior to chemotherapy initiation)
- Master platform exclusion criteria:
- Participant is deemed unlikely to survive \>30 days (as determined by clinical team)
- Participant unable to provide informed consent MYELO-CAN TXA exclusion criteria:
- Known allergy to tranexamic acid
- Active thromboembolic disease
- Active ischemic heart disease
- Gross hematuria
- Stage V chronic kidney disease
- Clinically suspected disseminated intravascular coagulation (DIC)
- Pregnancy and/or breastfeeding
The study team makes the final eligibility decision.
Where it's taking place
- Winnipeg, Manitoba, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Winnipeg, Manitoba, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.